Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | CD19 CAR T-cell therapy for lymphoma

Michael Schmitt • 26 Apr 2019
EBMT 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Michael Schmitt, MHBA, of University Hospital Heidelberg, Germany discusses CD19 CAR T-cell therapy against acute- and non-Hodgkin lymphoma. Being the 4th trial of its kind worldwide, Prof. Schmitt examines the need for new technology therapies to prevent patient relapse. This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting 2019, held in Frankfurt, Germany.

More from Michael Schmitt

2:46
Pros and cons of autologous and allogeneic CAR-Ts
Michael Schmitt • 7 Feb 2022
4:25
Exciting developments in the CAR space: novel target antigens, CAR-NKs & switchable CAR-Ts
Michael Schmitt • 7 Feb 2022
4:17
Preparing for the commercialization of CAR-T products
Michael Schmitt • 7 Feb 2022
1:11
Side effects of CAR T-cell therapy
Michael Schmitt • 10 Apr 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals